PON1 Deficiency Promotes TREM2 Pathway-Mediated Microglial Phagocytosis and Inhibits Pro-Inflammatory Cytokines Release in Vitro and in Vivo
Abstract Paraoxonase 1 (PON1) plays an anti-inflammatory role in the cardiovascular system. Levels of serum PON1 and polymorphisms in this gene were linked to Alzheimer disease (AD) and Parkinson disease (PD), but its function in the neuroimmune system and AD are not clear. To address this issue, we used PON1 knockout rats previously generated by our lab to investigate the role of PON1 in microglia. Knockout of PON1 in rat brain tissues protected against LPS-induced microglia activation. PON1 deficiency in rat primary microglia increased TREM2 (triggering receptor expressed in myeloid cells 2) expression, phagocytosis and IL-10 (M2-phenotype marker) release, but decreased production of pro-inflammatory cytokines such as IL-1β, IL-6, IL-12, IL-18 especially TNF-α (M1-phenotype markers) induced by LPS. PON1 deficiency in rat primary microglia activated TREM2 pathway but decreased LPS-induced ERK activation. The phagocytosis promoting effect of PON1 knockout could be reversed by administration of recombinant PON1 protein. The interaction between PON1 and TREM2 was verified by co-immunoprecipitation (co-IP) using rat brain tissues or over-expressed BV2 cell lysates, which might be involved in lysosomal degradation of TREM2. Furthermore, PON1 knockout may also enhance microglial phagocytosis and clearance of exogenous Aβ by an intrahippocampal injection and decrease the transcription of cytokines such as IL-1β, IL-6 and TNF-α in vivo. These results suggest an inhibitory role of PON1 in microglial phagocytosis dependent on its interaction with TREM2. These findings provide novel insights into the role of PON1 in neuroinflammation and highlight TREM2 as a potential target for Alzheimer’s disease therapy.